Catalent (CTLT.US) shares gain over 11% after publishing preliminary results for the first quarter of the fiscal year 2023/2024 and providing forecasts for the entire year. The company's stock price is rising despite a record loss recorded in the ended period.
Financial Summary
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app-
Net revenue of $982 million, a decrease of 3.9% year-over-year.
- Biologics net revenue: $447 million, a 15% decrease year-over-year, above the estimated $426.9 million.
- Net revenue from pharmaceuticals and consumer health: increased by 7.2% year-over-year, to $535 million.
-
Net loss of $715 million, including non-cash write-downs of the company's value amounting to $700 million.
-
Adjusted EBITDA of $115 million, a decrease of 38% year-over-year.
Forecasts for the entire fiscal year:
- Net revenue: $4.3 - $4.5 billion.
- Adjusted EBITDA: $680 - $760 million.
- Net profit: $113 - $175 million.
In their commentary, the management emphasized Catalent's strategic achievements, including the strategic review initiated in August and changes in the board after a settlement with Elliott Investment Management. Despite these challenges, Catalent expects that the majority of its pre-filled syringe production capacities until 2026 will be fully booked in the short period, due to high demand for new weight-loss drugs from Danish drugmaker Novo Nordisk's Wegovy.
Catalent (CTLT.US) shares are gaining over 11% in today's trading. The increases are driven by optimistic forecasts and positive management sentiment. However, the company's recent problems have pushed its stock price to multi-year lows this year. The current rebound is still a fraction of the share price at the peak of the pandemic bull market, at $140 per share. The current increase is capped by levels of $46 and $51, and breaking through these levels could indicate a breakout from consolidation. Source: xStation 5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
